<DOC>
	<DOCNO>NCT00044135</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness 12 week treatment clevudine , one three dos , patient chronically infect hepatitis B virus .</brief_summary>
	<brief_title>A Safety Study Evaluate 12 Weeks Treatment Clevudine Patients Infected Hepatitis B Virus .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>HBV DNA positive DNA level screen great equal 3,000,000 copies/mL . Documented HBsAg positive &gt; 6 month OR HBsAg positive IgM antiHBc negative antiHBs negative . Patients may HBeAg positive , antiHBe negative OR HBeAg negative ( precore mutant ) antiHBe positive . HBeAg positive antiHBe negative OR HBeAg negative ( precore mutant ) antiHBe positive positive HBsAg previous 6 month AST ALT level less equal 10 time upper limit normal . Bilirubin level less equal 1.5 x ULN bilirubin level &gt; 1.5 x ULN diagnosis Gilbert â€™ disease conjugate bilirubin within normal limit . Currently receive antiviral , immunomodulatory corticosteroid therapy Previous treatment lamivudine , lobucavir , adefovir , famciclovir , investigational nucleoside HBV infection Previous treatment interferon must end least 6 month prior screen visit History ascites , variceal hemorrhage hepatic encephalopathy Coinfection HCV HIV Evidence cirrhosis hepatocellular carcinoma ( alpha fetoprotein )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>clevudine</keyword>
	<keyword>hepatitis B</keyword>
</DOC>